# cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC

> **NCT05025592** · — · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 60 (estimated)

## Conditions studied

- HCC
- Transarterial Chemoembolization
- Hepatic Arterial Infusion Chemotherapy
- Regorafenib

## Interventions

- **DRUG:** Regorafenib
- **DEVICE:** cTACE/DEB-TACE-HAIC

## Key facts

- **NCT ID:** NCT05025592
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-10
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025592, "cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05025592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*